US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Procaps

1.01

0.0000

Volume:- -

Turnover:- -

Market Cap:113.95M

PE:1.96

High:1.01

Open:1.01

Low:1.01

Close:1.01

52wk High:3.84

52wk Low:0.5000

Shares:112.82M

Float Shares:19.15M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.5158

EPS(LYR):0.4207

ROE:373.70%

ROA:6.28%

PB:2.89

PE(LYR):2.40

Loading ...

Overview Company News Filings

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PROC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PROC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PROC\",,,,,undefined,":{"symbol":"PROC","market":"US","secType":"STK","nameCN":"Procaps","latestPrice":1.01,"timestamp":1755892800000,"preClose":1.01,"halted":4,"volume":0,"delay":0,"floatShares":19147990,"shares":112824183,"eps":0.515793,"marketStatus":"Delisted","change":0,"latestTime":"08-22 16:00:00 EDT","open":1.01,"high":1.01,"low":1.01,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.515793,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756108800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.01,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PROC\",,,,,undefined,":{"symbol":"PROC","floatShares":19147990,"roa":"6.28%","roe":"373.70%","lyrEps":0.420729,"shares":112824183,"dividePrice":0,"high":1.01,"amplitude":0,"preClose":1.01,"low":1.01,"week52Low":0.5,"pbRate":"2.89","psRate":"0.28","week52High":3.84,"institutionHeld":0,"latestPrice":1.01,"eps":0.515793,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.515793,"open":1.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PROC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"PROC","reason":null,"defaultRemindTime":1738679400000,"announcedDate":"2025-02-03","type":"delisting","dateTimestamp":1738645200000},{"market":"US","date":"2023-12-26","symbol":"PROC","fiscalQuarterEnding":"2023/09","expectedEps":0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1703566800000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2023-09-05","symbol":"PROC","fiscalQuarterEnding":"2023/06","expectedEps":0.06,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1693886400000,"reportTimeType":"pre","actualEps":0.27}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PROC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PROC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1694062800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PROC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PROC","date":"2025-01-31","current":3.436401,"percent":0.376079,"low":-132.08308,"twenty":-14.467484,"median":4.777205,"eighty":8.574248,"high":15.174275,"avg":-17.238194,"sd":45.468463,"marketCap":179390450},"quantilePoints":[{"date":"2021-10-01","current":-103.67686,"twenty":-108.860703,"median":-106.916762,"eighty":-104.972821,"marketCap":1083112156},{"date":"2021-10-08","current":-108.752706,"twenty":-108.752706,"median":-107.996729,"eighty":-104.540834,"marketCap":1136139522},{"date":"2021-10-15","current":-104.216844,"twenty":-108.601511,"median":-104.378839,"eighty":-103.784857,"marketCap":1088753365},{"date":"2021-10-22","current":-109.832674,"twenty":-109.61668,"median":-104.540834,"eighty":-102.985681,"marketCap":1147421941},{"date":"2021-10-29","current":-112.316598,"twenty":-109.61668,"median":-105.890793,"eighty":-103.784857,"marketCap":1173371503},{"date":"2021-11-05","current":-107.996729,"twenty":-109.61668,"median":-106.484775,"eighty":-104.216844,"marketCap":1128241830},{"date":"2021-11-12","current":-111.236631,"twenty":-109.61668,"median":-106.214783,"eighty":-104.216844,"marketCap":1162089084},{"date":"2021-11-19","current":-9.268173,"twenty":-108.752706,"median":-106.484775,"eighty":-104.216844,"marketCap":1106805235},{"date":"2021-11-26","current":-121.140525,"twenty":-109.832674,"median":-106.484775,"eighty":-104.216844,"marketCap":1061675562},{"date":"2021-12-03","current":-127.062379,"twenty":-111.236631,"median":-106.808765,"eighty":-104.216844,"marketCap":1113574686},{"date":"2021-12-10","current":-128.735946,"twenty":-121.140525,"median":-107.456745,"eighty":-104.216844,"marketCap":1128241830},{"date":"2021-12-17","current":-113.931312,"twenty":-120.239373,"median":-108.050727,"eighty":-104.540834,"marketCap":998494019},{"date":"2021-12-23","current":-123.329036,"twenty":-122.505126,"median":-108.482715,"eighty":-105.059218,"marketCap":1080855673},{"date":"2021-12-31","current":-125.517547,"twenty":-123.354783,"median":-109.832674,"eighty":-105.275212,"marketCap":1100035784},{"date":"2022-01-07","current":-119.72443,"twenty":-123.560761,"median":-110.804644,"eighty":-105.296811,"marketCap":1049264901},{"date":"2022-01-14","current":-117.79339,"twenty":-123.354783,"median":-112.316598,"eighty":-105.469605,"marketCap":1032341274},{"date":"2022-01-21","current":-117.535919,"twenty":-123.38053,"median":-113.931312,"eighty":-105.707199,"marketCap":1030084790},{"date":"2022-01-28","current":-120.110637,"twenty":-123.251794,"median":-116.184191,"eighty":-105.85429,"marketCap":1052649627},{"date":"2022-02-04","current":-122.299149,"twenty":-123.123058,"median":-117.664654,"eighty":-105.913256,"marketCap":1071829738},{"date":"2022-02-11","current":-114.9612,"twenty":-122.994322,"median":-117.664654,"eighty":-106.203983,"marketCap":1007519954},{"date":"2022-02-18","current":-102.602549,"twenty":-122.556621,"median":-117.535919,"eighty":-105.913256,"marketCap":899208738},{"date":"2022-02-25","current":-115.991087,"twenty":-122.299149,"median":-115.991087,"eighty":-105.897489,"marketCap":1016545888},{"date":"2022-03-04","current":-121.655469,"twenty":-122.299149,"median":-116.634767,"eighty":-106.101231,"marketCap":1066188529},{"date":"2022-03-11","current":-115.476143,"twenty":-122.299149,"median":-116.763503,"eighty":-106.352246,"marketCap":1012032921},{"date":"2022-03-18","current":-108.395666,"twenty":-122.299149,"median":-115.926719,"eighty":-106.352246,"marketCap":949979620},{"date":"2022-03-25","current":-114.31752,"twenty":-122.299149,"median":-115.733615,"eighty":-106.419977,"marketCap":1001878745},{"date":"2022-04-01","current":-108.524402,"twenty":-122.299149,"median":-114.9612,"eighty":-106.527974,"marketCap":951107862},{"date":"2022-04-08","current":-109.425554,"twenty":-122.299149,"median":-114.31752,"eighty":-106.63597,"marketCap":959005555},{"date":"2022-04-14","current":-102.988757,"twenty":-122.247655,"median":-112.532592,"eighty":-106.344068,"marketCap":902593464},{"date":"2022-04-22","current":-102.988757,"twenty":-122.01593,"median":-111.807813,"eighty":-105.881721,"marketCap":902593464},{"date":"2022-04-29","current":-102.988757,"twenty":-121.861447,"median":-110.912641,"eighty":-105.577602,"marketCap":902593464},{"date":"2022-05-06","current":-8.389413,"twenty":-121.655469,"median":-110.70478,"eighty":-104.870611,"marketCap":846181372},{"date":"2022-05-13","current":-8.614026,"twenty":-121.55248,"median":-109.832674,"eighty":-104.216844,"marketCap":868836468},{"date":"2022-05-20","current":-8.814477,"twenty":-121.114778,"median":-109.489922,"eighty":-103.71947,"marketCap":889054562},{"date":"2022-05-27","current":-8.959893,"twenty":-120.960295,"median":-109.425554,"eighty":-103.040251,"marketCap":903721705},{"date":"2022-06-03","current":-10.514843,"twenty":-120.754317,"median":-109.425554,"eighty":-102.812886,"marketCap":1060558602},{"date":"2022-06-10","current":-10.112039,"twenty":-120.239373,"median":-109.425554,"eighty":-101.408929,"marketCap":1019930614},{"date":"2022-06-17","current":-14.275795,"twenty":-120.110637,"median":-109.425554,"eighty":-14.897944,"marketCap":957877313},{"date":"2022-06-24","current":-14.460758,"twenty":-119.90466,"median":-108.752706,"eighty":-14.460758,"marketCap":970287973},{"date":"2022-07-01","current":-14.309425,"twenty":-119.853166,"median":-108.331299,"eighty":-14.460758,"marketCap":960133797},{"date":"2022-07-08","current":-14.763426,"twenty":-119.775924,"median":-108.158725,"eighty":-14.470847,"marketCap":990596326},{"date":"2022-07-15","current":-14.696166,"twenty":-119.72443,"median":-107.996729,"eighty":-14.47421,"marketCap":986083359},{"date":"2022-07-22","current":-14.29261,"twenty":-119.415464,"median":-107.47563,"eighty":-14.460758,"marketCap":959005555},{"date":"2022-07-29","current":-13.788165,"twenty":-119.209486,"median":-106.916762,"eighty":-14.34978,"marketCap":925158300},{"date":"2022-08-05","current":-12.863349,"twenty":-119.132244,"median":-106.64677,"eighty":-14.215262,"marketCap":863104999},{"date":"2022-08-12","current":-13.334165,"twenty":-118.926267,"median":-106.464627,"eighty":-13.989943,"marketCap":894695771},{"date":"2022-08-19","current":-12.871757,"twenty":-118.591553,"median":-106.356335,"eighty":-13.785878,"marketCap":863669120},{"date":"2022-08-26","current":-12.577497,"twenty":-118.43707,"median":-105.944791,"eighty":-13.145838,"marketCap":843924888},{"date":"2022-09-02","current":-11.241206,"twenty":-118.282587,"median":-105.6748,"eighty":-12.917157,"marketCap":824744777},{"date":"2022-09-09","current":-11.225828,"twenty":-118.128104,"median":-105.296811,"eighty":-12.678386,"marketCap":823616535},{"date":"2022-09-16","current":-10.718359,"twenty":-117.947873,"median":-104.79106,"eighty":-12.27483,"marketCap":786384555},{"date":"2022-09-23","current":-10.449247,"twenty":-117.79339,"median":-104.378839,"eighty":-11.419589,"marketCap":766640323},{"date":"2022-09-30","current":-10.764492,"twenty":-117.79339,"median":-104.216844,"eighty":-11.225828,"marketCap":789769281},{"date":"2022-10-07","current":-10.249335,"twenty":-117.741896,"median":-103.783384,"eighty":-11.179695,"marketCap":751973179},{"date":"2022-10-14","current":-10.149379,"twenty":-117.664654,"median":-103.246229,"eighty":-10.856759,"marketCap":744639607},{"date":"2022-10-21","current":-10.764492,"twenty":-117.61316,"median":-102.988757,"eighty":-10.736812,"marketCap":789769281},{"date":"2022-10-28","current":-10.472313,"twenty":-117.535919,"median":-102.812886,"eighty":-10.673394,"marketCap":768332686},{"date":"2022-11-04","current":-10.795248,"twenty":-117.226953,"median":-101.958869,"eighty":-10.656848,"marketCap":792025764},{"date":"2022-11-11","current":-10.764492,"twenty":-116.660514,"median":-100.868945,"eighty":-10.656848,"marketCap":789769281},{"date":"2022-11-18","current":12.895158,"twenty":-116.300053,"median":-57.849628,"eighty":-10.621478,"marketCap":775102137},{"date":"2022-11-25","current":12.407131,"twenty":-115.96534,"median":-14.923167,"eighty":-10.480819,"marketCap":745767849},{"date":"2022-12-02","current":12.125578,"twenty":-115.862351,"median":-14.830685,"eighty":-10.380046,"marketCap":728844222},{"date":"2022-12-09","current":11.731403,"twenty":-115.836604,"median":-14.696166,"eighty":-10.278552,"marketCap":705151143},{"date":"2022-12-16","current":11.787713,"twenty":-115.682121,"median":-14.628907,"eighty":-10.198952,"marketCap":708535869},{"date":"2022-12-23","current":10.098391,"twenty":-115.373154,"median":-14.612092,"eighty":-10.149379,"marketCap":606994104},{"date":"2022-12-30","current":9.854378,"twenty":-114.9612,"median":-14.570055,"eighty":-10.112039,"marketCap":592326960},{"date":"2023-01-06","current":8.897096,"twenty":-114.9612,"median":-14.498592,"eighty":-9.995706,"marketCap":534786627},{"date":"2023-01-13","current":9.347582,"twenty":-114.652234,"median":-14.469166,"eighty":-9.490104,"marketCap":561864431},{"date":"2023-01-20","current":8.44661,"twenty":-114.420509,"median":-14.460758,"eighty":-9.285179,"marketCap":507708823},{"date":"2023-01-27","current":8.089975,"twenty":-114.085795,"median":-14.343054,"eighty":-8.8279,"marketCap":486272228},{"date":"2023-02-03","current":7.789651,"twenty":-113.09208,"median":-14.29261,"eighty":-8.66047,"marketCap":468220359},{"date":"2023-02-10","current":7.414246,"twenty":-112.402996,"median":-14.124462,"eighty":-8.521406,"marketCap":445655522},{"date":"2023-02-17","current":6.90745,"twenty":-112.126803,"median":-14.057202,"eighty":-8.389413,"marketCap":415192993},{"date":"2023-02-24","current":7.864732,"twenty":-111.846305,"median":-13.83861,"eighty":-8.243997,"marketCap":472733326},{"date":"2023-03-03","current":7.526868,"twenty":-111.463864,"median":-13.785307,"eighty":7.425509,"marketCap":452424973},{"date":"2023-03-10","current":8.46538,"twenty":-111.107035,"median":-13.334165,"eighty":7.560655,"marketCap":508837065},{"date":"2023-03-17","current":7.71457,"twenty":-110.83275,"median":-13.115572,"eighty":7.673276,"marketCap":463707392},{"date":"2023-03-24","current":8.972177,"twenty":-110.712913,"median":-12.947423,"eighty":7.744603,"marketCap":539299594},{"date":"2023-03-31","current":8.46538,"twenty":-110.706407,"median":-12.821312,"eighty":7.819684,"marketCap":508837065},{"date":"2023-04-06","current":8.840785,"twenty":-110.58865,"median":-12.594312,"eighty":7.879748,"marketCap":531401901},{"date":"2023-04-14","current":8.634312,"twenty":-110.091866,"median":-12.27483,"eighty":8.048681,"marketCap":518991241},{"date":"2023-04-21","current":9.19742,"twenty":-109.828492,"median":-12.195568,"eighty":8.086221,"marketCap":552838496},{"date":"2023-04-28","current":8.409069,"twenty":-109.760268,"median":-11.333473,"eighty":8.281432,"marketCap":505452339},{"date":"2023-05-05","current":8.559231,"twenty":-109.528543,"median":-11.241206,"eighty":8.405315,"marketCap":514478274},{"date":"2023-05-12","current":8.507613,"twenty":-109.425554,"median":-11.225828,"eighty":8.461626,"marketCap":511375609},{"date":"2023-05-19","current":11.961379,"twenty":-109.425554,"median":-11.225828,"eighty":8.48415,"marketCap":508837065},{"date":"2023-05-26","current":11.27181,"twenty":-109.425554,"median":-11.118183,"eighty":8.518875,"marketCap":479502777},{"date":"2023-06-02","current":12.067467,"twenty":-109.425554,"median":-10.99516,"eighty":8.545154,"marketCap":513350032},{"date":"2023-06-09","current":14.933211,"twenty":-109.425554,"median":-10.85676,"eighty":8.559231,"marketCap":488539994},{"date":"2023-06-16","current":15.174275,"twenty":-109.425554,"median":-10.764492,"eighty":8.634312,"marketCap":496426405},{"date":"2023-06-23","current":14.725944,"twenty":-109.425554,"median":-10.764492,"eighty":8.664345,"marketCap":481759261},{"date":"2023-06-30","current":13.794795,"twenty":-109.425554,"median":-10.749115,"eighty":8.724409,"marketCap":451296732},{"date":"2023-07-07","current":13.518899,"twenty":-109.425554,"median":-10.718359,"eighty":8.833277,"marketCap":442270797},{"date":"2023-07-14","current":13.96723,"twenty":-109.425554,"median":-10.708286,"eighty":8.915866,"marketCap":456937941},{"date":"2023-07-21","current":14.346587,"twenty":-109.156415,"median":-10.656848,"eighty":9.099815,"marketCap":469348601},{"date":"2023-07-28","current":13.484413,"twenty":-108.752706,"median":-10.639547,"eighty":9.219944,"marketCap":441142555},{"date":"2023-08-04","current":13.617877,"twenty":-108.661384,"median":-10.609791,"eighty":9.358844,"marketCap":445508851},{"date":"2023-08-11","current":13.760308,"twenty":-108.472908,"median":-10.46078,"eighty":9.465834,"marketCap":450168490},{"date":"2023-08-18","current":13.484413,"twenty":-108.344172,"median":-10.380046,"eighty":10.015802,"marketCap":441142555},{"date":"2023-08-25","current":13.449926,"twenty":-108.245248,"median":-10.341601,"eighty":11.332277,"marketCap":440014313},{"date":"2023-09-01","current":13.449926,"twenty":-108.169524,"median":-10.272401,"eighty":11.586733,"marketCap":440014313},{"date":"2023-09-08","current":6.269046,"twenty":-108.085673,"median":-10.235084,"eighty":11.483985,"marketCap":417449477},{"date":"2023-09-15","current":6.031838,"twenty":-108.006913,"median":-10.180134,"eighty":11.376333,"marketCap":401654091},{"date":"2023-09-22","current":5.981008,"twenty":-107.996729,"median":-10.149379,"eighty":11.363505,"marketCap":398269365},{"date":"2023-09-29","current":6.060812,"twenty":-107.896286,"median":-10.136302,"eighty":11.334752,"marketCap":403583385},{"date":"2023-10-06","current":5.845461,"twenty":-107.486961,"median":-10.087867,"eighty":11.314244,"marketCap":389243431},{"date":"2023-10-13","current":4.93052,"twenty":-107.348748,"median":-9.980605,"eighty":11.067159,"marketCap":328318372},{"date":"2023-10-20","current":4.049465,"twenty":-106.916762,"median":-9.530373,"eighty":10.218521,"marketCap":269649797},{"date":"2023-10-27","current":5.049123,"twenty":-106.916762,"median":-9.519187,"eighty":10.158456,"marketCap":336216065},{"date":"2023-11-03","current":4.87969,"twenty":-106.799964,"median":-9.305964,"eighty":9.974508,"marketCap":324933647},{"date":"2023-11-10","current":4.583181,"twenty":-106.7093,"median":-9.161239,"eighty":9.869394,"marketCap":305189415},{"date":"2023-11-17","current":4.032521,"twenty":-106.63597,"median":-8.825662,"eighty":9.741757,"marketCap":268521555},{"date":"2023-11-24","current":4.811916,"twenty":-106.549573,"median":-8.747362,"eighty":9.587841,"marketCap":320420679},{"date":"2023-12-01","current":4.201955,"twenty":-106.476716,"median":-8.614026,"eighty":9.465834,"marketCap":279803973},{"date":"2023-12-08","current":5.286161,"twenty":-106.464627,"median":-8.557201,"eighty":9.460203,"marketCap":352000168},{"date":"2023-12-15","current":5.03218,"twenty":-106.429487,"median":-8.434157,"eighty":9.430171,"marketCap":335087823},{"date":"2023-12-22","current":5.659084,"twenty":-106.360423,"median":-8.389413,"eighty":9.377614,"marketCap":376832771},{"date":"2023-12-29","current":8.947611,"twenty":-106.352246,"median":-8.389413,"eighty":9.37386,"marketCap":467092117},{"date":"2024-01-05","current":9.077286,"twenty":-106.310144,"median":-8.34467,"eighty":9.362598,"marketCap":473861568},{"date":"2024-01-12","current":9.876952,"twenty":-106.154682,"median":3.744484,"eighty":9.445187,"marketCap":515606516},{"date":"2024-01-19","current":9.206962,"twenty":-105.944791,"median":4.015578,"eighty":9.460203,"marketCap":480631019},{"date":"2024-01-26","current":8.882773,"twenty":-105.865954,"median":4.07488,"eighty":9.460203,"marketCap":463707392},{"date":"2024-02-02","current":7.922526,"twenty":-105.836795,"median":4.201955,"eighty":9.385122,"marketCap":413579607},{"date":"2024-02-09","current":7.326667,"twenty":-105.512804,"median":4.273964,"eighty":9.379862,"marketCap":382473980},{"date":"2024-02-16","current":7.715693,"twenty":-105.296811,"median":4.303615,"eighty":9.366352,"marketCap":402782333},{"date":"2024-02-23","current":7.725203,"twenty":-105.296811,"median":4.337502,"eighty":9.351336,"marketCap":403278759},{"date":"2024-03-01","current":6.310875,"twenty":-105.210413,"median":4.489992,"eighty":9.304246,"marketCap":329446614},{"date":"2024-03-08","current":6.570226,"twenty":-104.870611,"median":4.676369,"eighty":9.291699,"marketCap":342985516},{"date":"2024-03-15","current":6.786352,"twenty":-104.688071,"median":4.752614,"eighty":9.291271,"marketCap":354267934},{"date":"2024-03-22","current":6.710708,"twenty":-104.565132,"median":4.811916,"eighty":9.258404,"marketCap":350319088},{"date":"2024-03-28","current":6.008299,"twenty":-104.34644,"median":4.811916,"eighty":9.250187,"marketCap":313651228},{"date":"2024-04-05","current":6.159587,"twenty":-104.216844,"median":4.845802,"eighty":9.241051,"marketCap":321548921},{"date":"2024-04-12","current":5.815515,"twenty":-104.216844,"median":4.896633,"eighty":9.218161,"marketCap":303587311},{"date":"2024-04-19","current":5.835398,"twenty":-104.175166,"median":4.938992,"eighty":9.201237,"marketCap":304625294},{"date":"2024-04-26","current":5.893968,"twenty":-103.992897,"median":5.015236,"eighty":9.190177,"marketCap":307682829},{"date":"2024-05-03","current":6.418938,"twenty":-103.762079,"median":5.057595,"eighty":9.181329,"marketCap":335087823},{"date":"2024-05-10","current":5.965074,"twenty":-103.495723,"median":5.08301,"eighty":9.178649,"marketCap":311394745},{"date":"2024-05-17","current":5.576047,"twenty":-103.297723,"median":5.193142,"eighty":9.156125,"marketCap":291086392},{"date":"2024-05-24","current":5.640885,"twenty":-103.246229,"median":5.286161,"eighty":9.12875,"marketCap":294471117},{"date":"2024-05-31","current":5.662498,"twenty":-103.14324,"median":5.420183,"eighty":9.103221,"marketCap":295599359},{"date":"2024-06-07","current":5.878623,"twenty":-102.988757,"median":5.554435,"eighty":9.072964,"marketCap":306881777},{"date":"2024-06-14","current":5.554435,"twenty":-102.988757,"median":5.586854,"eighty":9.060759,"marketCap":289958150},{"date":"2024-06-21","current":5.673304,"twenty":-102.988757,"median":5.619272,"eighty":9.037873,"marketCap":296163480},{"date":"2024-06-28","current":5.424759,"twenty":-102.918409,"median":5.619272,"eighty":9.019103,"marketCap":283188699},{"date":"2024-07-05","current":5.403147,"twenty":-102.770819,"median":5.608466,"eighty":8.987193,"marketCap":282060457},{"date":"2024-07-12","current":5.424759,"twenty":-102.525307,"median":5.554435,"eighty":8.967264,"marketCap":283188699},{"date":"2024-07-15","current":5.554435,"twenty":-102.448066,"median":5.554435,"eighty":8.962351,"marketCap":289958150},{"date":"2024-08-02","current":5.208633,"twenty":-102.370824,"median":5.554435,"eighty":8.957437,"marketCap":271906281},{"date":"2024-08-09","current":4.387355,"twenty":-101.907375,"median":5.43179,"eighty":8.928564,"marketCap":229033091},{"date":"2024-08-16","current":4.171229,"twenty":-101.525916,"median":5.424759,"eighty":8.915866,"marketCap":217750673},{"date":"2024-08-23","current":4.322517,"twenty":-101.084939,"median":5.413502,"eighty":8.908977,"marketCap":225648366},{"date":"2024-08-30","current":4.257679,"twenty":-100.804147,"median":5.403147,"eighty":8.900012,"marketCap":222263640},{"date":"2024-09-06","current":3.976716,"twenty":-100.467701,"median":5.403147,"eighty":8.891367,"marketCap":207596496},{"date":"2024-09-13","current":3.976716,"twenty":-66.285269,"median":5.269303,"eighty":8.880994,"marketCap":207596496},{"date":"2024-09-20","current":3.890265,"twenty":-15.382212,"median":5.208633,"eighty":8.863309,"marketCap":203083529},{"date":"2024-09-27","current":4.668319,"twenty":-14.928211,"median":5.142312,"eighty":8.833277,"marketCap":243700235},{"date":"2024-10-04","current":4.841219,"twenty":-14.891218,"median":5.08301,"eighty":8.814418,"marketCap":252726169},{"date":"2024-10-11","current":4.234044,"twenty":-14.860951,"median":5.040652,"eighty":8.795603,"marketCap":221029795},{"date":"2024-10-18","current":4.408968,"twenty":-14.803781,"median":4.964406,"eighty":8.780568,"marketCap":230161333},{"date":"2024-10-25","current":4.063166,"twenty":-14.736522,"median":4.922048,"eighty":8.77471,"marketCap":212109464},{"date":"2024-10-31","current":3.890265,"twenty":-14.696166,"median":4.888161,"eighty":8.769155,"marketCap":203083529},{"date":"2024-11-08","current":3.609302,"twenty":-14.68944,"median":4.841219,"eighty":8.739426,"marketCap":188416385},{"date":"2024-11-15","current":1.718201,"twenty":-14.655811,"median":4.835039,"eighty":8.705166,"marketCap":89695225},{"date":"2024-11-22","current":2.398997,"twenty":-14.625544,"median":4.811916,"eighty":8.684979,"marketCap":125234843},{"date":"2024-11-29","current":3.2635,"twenty":-14.612092,"median":4.811916,"eighty":8.671853,"marketCap":170364516},{"date":"2024-12-06","current":3.209469,"twenty":-14.612092,"median":4.777205,"eighty":8.671853,"marketCap":167543911},{"date":"2024-12-13","current":5.057345,"twenty":-14.612092,"median":4.811916,"eighty":8.662468,"marketCap":264008588},{"date":"2024-12-20","current":5.273471,"twenty":-14.595277,"median":4.811916,"eighty":8.653083,"marketCap":275291006},{"date":"2024-12-27","current":5.338309,"twenty":-14.554922,"median":4.824233,"eighty":8.638066,"marketCap":278675732},{"date":"2025-01-03","current":5.035733,"twenty":-14.524655,"median":4.841219,"eighty":8.634312,"marketCap":262880346},{"date":"2025-01-10","current":3.630914,"twenty":-14.501114,"median":4.835039,"eighty":8.634312,"marketCap":189544627},{"date":"2025-01-17","current":3.782203,"twenty":-14.482618,"median":4.811916,"eighty":8.612764,"marketCap":197442320},{"date":"2025-01-24","current":3.587689,"twenty":-14.475892,"median":4.811916,"eighty":8.579954,"marketCap":187288143},{"date":"2025-01-31","current":3.436401,"twenty":-14.467484,"median":4.777205,"eighty":8.574248,"marketCap":179390450}],"updateTime":1755892723219},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PROC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520383941","title":"Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein","url":"https://stock-news.laohu8.com/highlight/detail?id=2520383941","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520383941?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:50","pubTimestamp":1742388600,"startTime":"0","endTime":"0","summary":"Company advancing development of its modified version of Interleukin-18  that exhibits wild-type binding to the IL-18 receptor , coupled with undetectable binding to the inhibitory IL-18 Binding Protein  thus making IL-18BPR more effective in vitro. Sonnet’s variant human IL-18BPR is a key cytokine which comprises substitutions at the following amino acid positions: Y1, M51, M60, S105 and D110, relative to human wildtype IL-18. Patent opens up potential licensing opportunities for rights to IL-18BPR independent of Sonnet’s FHAB platform patent estate. Management releases “What This Means” segment discussing the allowed patent; Access here. Sonnet previously reported the generation of two novel drug candidates, SON-1411  and SON-1400 , each containing a variant version of recombinant human interleukin-18 . SON-1411 is a proprietary bifunctional fusion protein consisting of IL-18BPR combined with single-chain wild-type IL-12, linked to Sonnet's Fully Human Albumin Binding  platform while","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonnet-biotherapeutics-receives-notice-allowance-125000901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0359201612.USD","IE00BYQNZ168.SGD","LU1023057109.AUD","BK4548","BK4007","BK4526","SONN","LU2039709279.SGD","BK4509","BK4565","BK4531","01698","IE00B12V2V27.USD","BK4563","BK4552","BK4139","BK4535","BK4571","LU0359202008.SGD","SG9999011746.SGD","IE00BYTNYN87.SGD","PROC","BK4108"],"gpt_icon":1},{"id":"2520757296","title":"Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520757296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520757296?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:19","pubTimestamp":1742228340,"startTime":"0","endTime":"0","summary":"Results from Phase 2 RAINFOLTM-01 trial  showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate  of 55.6% and median duration of response  was not reached. The B1 cohort is a dose expansion study in patients with histologically or cytologically confirmed advanced OC . Rina-S 120 mg/m2 Q3W at a median on-study follow-up of 48 weeks showed encouraging antitumor activity; the confirmed ORR was 55.6% , the disease control rate  was 88.9% , and the median duration of response  was not reached . In the 18 patients evaluable for response treated with 120 mg/m2 Q3W, complete responses were observed in 4 patients  and 8 patients experienced confirmed partial responses . Most responses with Rina-S 120 mg/m2 were observed early . Only one patient in the 120 mg/m2 treatment arm was not evaluable. In the Rina-S 100 mg/m2 Q3W treatment arm , at a median on study follow-up of 46 weeks, the confirmed ORR was 22.7% , the DCR was 86.4% , and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigational-rinatabart-sesutecan-rina-continues-161900141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2298321311.HKD","PLD","IE00B66KJ199.SGD","OC","BK4224","LU2023250843.SGD","LU2048586759.USD","BK4171","BK4567","BK4585","LU2023250504.SGD","LU2360108059.USD","BK4086","IE00B2PGVK34.USD","LU2092937221.SGD","BK4588","LU0868494617.USD","BK4534","IE00B19Z4B17.USD","BK4157","BK4007","BK4080","BK4139","PROC","LU2106854487.HKD","IE00BGHQF417.EUR","BK4231","IE00B3CCJ633.GBP","ORR","ADC","IE0031619046.USD","LU1917777945.USD","IE00B7SZL793.SGD","GMAB","LU1974910355.USD","AEIS","LU2041044095.USD"],"gpt_icon":0},{"id":"2519314984","title":"Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2519314984","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519314984?lang=en_us&edition=fundamental","pubTime":"2025-03-15 23:25","pubTimestamp":1742052300,"startTime":"0","endTime":"0","summary":"Azenosertib median duration of response  updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer  and continues to demonstrate an objective response rate  of ~35% in response-evaluable patients. On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026. As of the January 13, 2025 data cutoff, the safety and tolerability profile was consistent with the safety and tolerability profile from the Company’s January 29, 2025 investor event, which included data based off a cutoff date of December 2, 2024, with no new safety findings. Gastrointestinal toxicities and fatigue were found to be the most common treatment-related adverse events.“The presentation of the updated DENALI Part 1b data at the SGO Annual Meeting supports our continued development of azenosertib,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “The clear anti-tumor a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-presents-updated-clinical-152500846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZNTL","BK4139","BK4007","PROC","ORR"],"gpt_icon":1},{"id":"2519313450","title":"ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2519313450","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519313450?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:00","pubTimestamp":1742040000,"startTime":"0","endTime":"0","summary":"Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer . Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology  Annual Meeting on Women's Cancer in Seattle. \"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options,\" said Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, AbbVie. \"We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers.\". In the United States, ovarian cancer is the leading cause of death from gynecological cancers.3 Each year, approximately 20,000 women","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","LU1430594728.SGD","BK4533","IE0002141913.USD","IE00B4R5TH58.HKD","LU1244550494.USD","LU1934455277.USD","PFS","BK4550","LU0820561818.USD","LU0170899867.USD","ADC","BK4080","LU1989772840.SGD","IE00BJJMRZ35.SGD","LU0738911758.USD","LU1162221912.USD","LU1989771016.USD","LU1244550577.SGD","LU2089984988.USD","BK4195","LU2237443465.HKD","LU1037948541.HKD","LU0320765646.SGD","LU0795875086.SGD","LU1003077747.HKD","LU0545039389.USD","LU0708994859.HKD","LU2237443895.HKD","LU1496350502.SGD","LU1291159041.SGD","LU1037948897.HKD","SG9999015952.SGD","BK4585","LU0985320562.USD","LU0417517546.SGD","BK4581","LU0965508806.USD","LU1267930573.SGD","LU1732799900.SGD","SG9999015986.USD","IE00BVYPNV92.GBP","LU1244550221.USD","LU1983299246.USD","PROC","LU2237443978.SGD","ORR","LU2089283258.USD","ABBV","LU2112291526.USD"],"gpt_icon":0},{"id":"2518746603","title":"Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746603","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518746603?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:45","pubTimestamp":1741697100,"startTime":"0","endTime":"0","summary":"On-demand video webcast now available here PRINCETON, N.J., March  11, 2025  (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage comp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040601/0/en/Sonnet-BioTherapeutics-Holdings-Inc-Participates-in-the-Virtual-Investor-Top-5-for-25-On-Demand-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PROC","SONN","BK4139"],"gpt_icon":0},{"id":"2516661716","title":"Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661716","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661716?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:00","pubTimestamp":1741039200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  03, 2025  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036085/0/en/Zentalis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","PROC","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","BK4585","BK4112","BK4588","BK4007",".IXIC","IE00B3QW5Z07.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2516332656","title":"Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516332656","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516332656?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC. Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs. SAN DIEGO, March 03, 2025  -- Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer , at the Society of Gynecologic Oncology  2025 Annual Meeting on Women’s Cancer, to be held on March 14-17 in Seattle, Washington.Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer : Outcomes from Part 1b of the DENALI Study . Session: Scientific Plenary II: Hitting the Target - Maximizing IMPA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-multiple-data-130000364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ZNTL","PROC","BK4139"],"gpt_icon":0},{"id":"2516680252","title":"Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680252","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680252?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:05","pubTimestamp":1741003500,"startTime":"0","endTime":"0","summary":"Initial clinical readout from Phase 1 RP-3467  POLAR trial expected in Q3 2025. Initial clinical readout from Phase 1 RP-1664  LIONS trial expected in Q4 2025. $152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027. CAMBRIDGE, Mass. & MONTREAL, March 03, 2025----Repare Therapeutics Inc.  , a clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2024.\"Our recently implemented re-structuring and the re-prioritization of our clinical portfolio meaningfully extends our cash runway into late 2027. We are now focused on three ongoing Phase 1 clinical trials with readouts expected in 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor; the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor; and our ongoing MYTHIC trial evaluating lunresertib in combination with Debiopharm's WEE1 inhibitor, Debio 0123,\" said Lloyd M. Segal, President and Chief Executive Office","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repare-therapeutics-provides-business-clinical-120500204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4139","BK4007","BK4211","EC","LENZ","PROC","BK4201","RPTX","BK4195"],"gpt_icon":0},{"id":"2514538478","title":"Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2514538478","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514538478?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:00","pubTimestamp":1740578400,"startTime":"0","endTime":"0","summary":"Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB)provides","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032957/0/en/Sonnet-BioTherapeutics-Presents-Compilation-of-Data-Highlighting-the-Potential-of-SON-1010-as-a-Monotherapy-or-a-Combination-Therapy-to-Improve-the-Treatment-of-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4108","BK4548","IE00BYTNYN87.SGD","LU0359201612.USD","LU0359202008.SGD","PROC","IE00BYQNZ168.SGD","SG9999011746.SGD","BK4136","IE00B12V2V27.USD","BK4509","BK4563","BK4526","BK4552","BK4531","BK4139","BK4007","BK4565","SONN","LU1023057109.AUD","BK4571","LU2039709279.SGD","SON","01698"],"gpt_icon":1},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4567","BK4006","CRS","ORR","BK4505","MTD","OS","BK4121","BK4548","BK4533","IE00B66KJ199.SGD","LU1878469433.USD","LU2413666426.HKD","IMCR","CM","ATOM","BK4195","BK4211","LU2413666699.HKD","BK4585","BK4139","LU2065731478.USD","LU1093756168.USD","LU0347712357.USD","IE0031619046.USD","BK4599","BK4147","BK4588","PROC","BK4207","IE00B19Z4B17.USD","ALT","PFS","CTA","BK4097","LU1721428933.USD","IE00BYQQ9H92.USD","BK4007","LU1093756325.SGD","IE00BFXG0V08.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2514706114","title":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706114","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706114?lang=en_us&edition=fundamental","pubTime":"2025-02-25 05:05","pubTimestamp":1740431100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  24, 2025  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031531/0/en/Zentalis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PROC"],"gpt_icon":0},{"id":"2512102123","title":"Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2512102123","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512102123?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:35","pubTimestamp":1739972100,"startTime":"0","endTime":"0","summary":"Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028787/0/en/Sonnet-BioTherapeutics-Announces-That-Its-Proprietary-Antibody-Drug-Conjugate-ADC-Platform-is-Available-for-Drug-Discovery-Partnerships-with-Potential-for-Producing-Multiple-Pipeli.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1721429741.USD","LU2380233275.USD","LU1721429402.USD","BK4007","BK4231","DAR","ADC","LU0256331488.USD","LU2308191902.HKD","PROC","BK4189","LU2211817866.USD","SONN","BK4080"],"gpt_icon":0},{"id":"2512638991","title":"Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2512638991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512638991?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:15","pubTimestamp":1739888100,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Feb.  18, 2025  (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic dr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3027970/0/en/Sonnet-BioTherapeutics-Selected-for-Poster-Presentation-at-the-2025-AACR-IO-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","SONN","BK4139","BK4007","PROC","IO","BK4179"],"gpt_icon":0},{"id":"2511754090","title":"Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2511754090","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511754090?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:30","pubTimestamp":1739453400,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Feb.  13, 2025  (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the \"Company\" or \"Sonnet\"), a clinical-stage company developing targeted immunotherapeutic dru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/13/3025878/0/en/Sonnet-BioTherapeutics-Appoints-Stephen-McAndrew-Ph-D-as-Chief-Business-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROC","SONN","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}]}}